What Iovance Biotherapeutics Inc's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 16 | 68 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 149,129 | 754,019 |
| Disposed | 63,448 | 319,273 |
| Net activity | +85,681 | +434,746 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Bilinsky Igor | Chief Operating Officer | Sep 08 | Withheld — tax / exercise cost · F | −3,976 | $8.70 | −$34.6K | 142,074 |
| Bilinsky Igor | Chief Operating Officer | Sep 08 | Exercise / conversion · M | +7,813 | — | — | 146,050 |
| Vogt Frederick G | Interim CEO & General Counsel | Sep 08 | Withheld — tax / exercise cost · F | −6,638 | $8.70 | −$57.8K | 595,447 |
| Vogt Frederick G | Interim CEO & General Counsel | Sep 08 | Exercise / conversion · M | +15,626 | — | — | 602,085 |
| Puri Raj K. | Chief Regulatory Officer | Sep 08 | Withheld — tax / exercise cost · F | −4,478 | $8.70 | −$39K | 256,364 |
| Puri Raj K. | Chief Regulatory Officer | Sep 08 | Exercise / conversion · M | +9,766 | — | — | 260,842 |
| Bilinsky Igor | Chief Operating Officer | Sep 01 | Withheld — tax / exercise cost · F | −4,472 | $8.28 | −$37K | 138,237 |
| Bilinsky Igor | Chief Operating Officer | Sep 01 | Exercise / conversion · M | +8,789 | — | — | 142,709 |
| Vogt Frederick G | Interim CEO & General Counsel | Sep 01 | Withheld — tax / exercise cost · F | −17,702 | $8.28 | −$147K | 586,459 |
| Vogt Frederick G | Interim CEO & General Counsel | Sep 01 | Exercise / conversion · M | +41,669 | — | — | 604,161 |
| Puri Raj K. | Chief Regulatory Officer | Sep 01 | Withheld — tax / exercise cost · F | −2,508 | $8.28 | −$20.8K | 251,076 |
| Puri Raj K. | Chief Regulatory Officer | Sep 01 | Exercise / conversion · M | +5,470 | — | — | 253,584 |
| Kirby Daniel Gordon | Chief Commercial Officer | Aug 10 | Withheld — tax / exercise cost · F | −2,436 | $6.40 | −$15.6K | 154,511 |
| Kirby Daniel Gordon | Chief Commercial Officer | Aug 10 | Exercise / conversion · M | +10,001 | — | — | 156,947 |
| Roche Corleen M. | Chief Financial Officer | Aug 06 | Withheld — tax / exercise cost · F | −21,238 | $6.21 | −$132K | 28,757 |
| Roche Corleen M. | Chief Financial Officer | Aug 06 | Exercise / conversion · M | +49,995 | — | — | 49,995 |
| Puri Raj K. | Chief Regulatory Officer | Jun 05 | Withheld — tax / exercise cost · F | −3,843 | $4.23 | −$16.3K | 248,114 |
| Puri Raj K. | Chief Regulatory Officer | Jun 05 | Exercise / conversion · M | +9,766 | — | — | 251,957 |
| Vogt Frederick G | Interim CEO & General Counsel | Jun 05 | Withheld — tax / exercise cost · F | −6,638 | $4.23 | −$28.1K | 562,492 |
| Vogt Frederick G | Interim CEO & General Counsel | Jun 05 | Exercise / conversion · M | +15,625 | — | — | 569,130 |
Loading...
